The potential application of rapamycin derivatives in UC therapy was supported by their ability to reduce cell viability in various bladder cancer-derived cell lines and in a mouse model of progressive bladder cancer in which p53 and PTEN are deleted in the bladder urothelium [9], [33], [34], [35], [36]. This evidence concerns the gene PTEN and urinary bladder cancer.